What are the NOF recommendations for pharmacologic therapy in the treatment of osteoporosis?

Updated: Jan 20, 2021
  • Author: Rachel Elizabeth Whitaker Elam, MD, MSc; Chief Editor: Herbert S Diamond, MD  more...
  • Print

The NOF recommends reserving pharmacologic therapy for postmenopausal women and men aged 50 years or older who present with the following [4] :

  • Fragility fracture: a hip or vertebral fracture (vertebral fractures may be clinical or morphometric (ie, identified on a radiograph alone)
  • T-score of –2.5 or less at the femoral neck, total hip, spine, or 33% of radius after appropriate evaluation to exclude secondary causes
  • Low bone mass (T-score of –1.0 to –2.5 at the femoral neck or spine) and a 10-year probability of a hip fracture of 3% or greater or a 10-year probability of a major osteoporosis-related fracture of 20% or greater, based on the US-adapted WHO algorithm for calculating fracture risk ( FRAX)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!